The Who, What, Where, When and Sometimes, Why.

Types of Breast Tumors

Although breast cancer is often referred to as one disease, there are many different types of breast cancer.

While all breast cancers start in the breast, they differ in other ways. They can be non-invasive or invasive. Tumor cells can vary in location (milk ducts or lobules) and how they look under a microscope. These differences often affect prognosis (chance of survival).

Tumor characteristics, such as hormone receptor status and HER2 status, also affect prognosis.

Learn more about factors that affect prognosis.

Non-invasive and invasive breast cancers

A pathologist looks at the tissue removed during a biopsy under a microscope to check whether a tumor is non-invasive breast cancer (ductal carcinoma in situ) or invasive breast cancer.

Ductal carcinoma in situ (DCIS)

Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer. In situ means “in place.” With DCIS, the abnormal cells are contained in the milk ducts of the breast and have not invaded nearby tissue outside the milk ducts.

Although DCIS is non-invasive, without treatment, the abnormal cells could progress to invasive breast cancer over time. Some people use the terms “pre-invasive” or “pre-cancerous” to describe DCIS.

With treatment, the chances of survival for DCIS are usually excellent.

Learn about breast anatomy.

Invasive breast cancer

Invasive breast cancer has spread from the original site (either the milk ducts or the lobules) into the nearby breast tissue, and possibly to nearby lymph nodes and other parts of the body. Invasive breast cancer that has spread beyond the breast and nearby lymph nodes is called metastatic breast cancer.

Invasive breast cancers, including metastatic breast cancer, have a poorer prognosis (chance of survival) than DCIS.

Learn about breast anatomy.

The following is a 3D interactive model showing non-invasive and invasive breast cancers (stages 0 to IV). Click the arrows to move through the model to learn more about breast cancer.

Types of invasive breast cancer

The table below lists types of invasive breast cancer.

Invasive ductal carcinoma is the most common type of breast cancer (70%-80% of all invasive breast cancers) [17-18]. It may also be called infiltrating ductal carcinoma, invasive carcinoma of no special type, or invasive carcinoma not otherwise specified.

Invasive lobular carcinoma is the next most common type (about 10%-15% of all invasive breast cancers) [17-18].

Prevalence and Tumor Characteristics of Different Types of Invasive Breast Cancer

Type of invasive breast cancer

Proportion of all invasive breast cancers

Tumor characteristics

Prognosis
(chance of survival)

Invasive ductal carcinoma (IDC)

70%-80%

  • Hard tumor texture
  • Tumor is irregular, star-shaped
  • Cell features vary
  • DCIS often present

  • Prognosis varies with stage and grade of tumor

Invasive lobular carcinoma (ILC)

10%-15%

  • Normal, slightly firm or hard tumor texture
  • Cells most often appear in single file order
  • Tumors are most often hormone receptor-positive and HER2-negative

  • Prognosis varies with stage and grade of tumor
  • Pattern of metastases may be slightly different from IDC (for example, ILC may metastasize to the gastrointestinal tract or the ovaries)

Tubular carcinoma

1%-2%

  • Tumors are most often small
  • Often no palpable tumor
  • Cells form tube-like structures
  • Tumors are almost always hormone receptor-positive and HER2-negative

  • Prognosis is usually better than for IDC
  • Rare for cancer to spread to lymph nodes or other parts of the body

Mucinous (colloid) carcinoma

2%

  • Soft tumor
  • Often no palpable tumor
  • Cells are surrounded by excess mucous (mucin)
  • Tumors are most often hormone receptor-positive and HER2-negative

  • More common among older women
  • Tends to have a good prognosis
  • Less common for cancer to spread to lymph nodes

Carcinomas with medullary features

1%

  • Soft tumor
  • Cells have a sheet-like appearance
  • Tumors tend to be triple negative (hormone receptor-negative and HER2-negative)

Invasive papillary carcinoma

1%

  • Soft tumor
  • Cells appear as fingerlike branches

  • More common in women after menopause
  • Tends to have a good prognosis

Adapted from select sources [17-19].

Special invasive breast cancers and carcinoma in situ

Click on the topics below to learn more.

Inflammatory breast cancer (also called IBC) is an aggressive breast cancer.

The main warning signs of inflammatory breast cancer are swelling and redness in the breast. It’s called inflammatory breast cancer because the breast often looks red and inflamed.

About 1% to 5% of breast cancers in the U.S. are inflammatory breast cancers [20-21].

Learn more about inflammatory breast cancer

Paget disease of the breast (Paget disease of the nipple) is a rare carcinoma in situ in the skin of the nipple or in the skin closely surrounding the nipple. It’s usually found with an underlying breast cancer.

About 1% to 3% of breast cancers also involve Paget disease of the breast [22].

Learn more about Paget disease of the breast.

Metaplastic breast cancer is rare, accounting for less than 1% of all invasive breast cancers [23].

Compared to more common breast cancers, metaplastic tumors are more likely to [18]:

Metaplastic breast cancers are also more likely to be triple negative [19,24-26]. Triple negative breast cancers are:

Diagnosis

Under a microscope, metaplastic tumor cells can look very different from the tumor cells of more common breast cancers. These cancers can be hard to diagnose and are often confused with other uncommon breast tumors or tumors that began in other parts of the body. So, it’s best to have the pathology slides reviewed by another pathologist to confirm the diagnosis.

You can request your health care provider send the slides out for review, or you may wish to get a second opinion with another pathologist for confirmation. You may need to sign a release giving your current health care provider permission to send the slides out for review.

Learn more about getting a second opinion.

 

Susan G. Komen® Support Resources

  • Do you need help? We’re here for you. The Komen Patient Care Center is your trusted, go-to source for timely, accurate breast health and breast cancer information, services and resources. Our navigators offer free, personalized support to patients, caregivers and family members, including education, emotional support, financial assistance, help accessing care and more. Get connected to a Komen navigator by contacting the Breast Care Helpline at 1-877-465-6636 or email helpline@komen.org to get started. All calls are answered Monday through Thursday, 9 a.m. to 7 p.m. ET and Friday, 9 a.m. to 6 p.m. ET. Se habla español.
  • The Komen Breast Cancer and Komen Metastatic (Stage IV) Breast Cancer Facebook groups are places where those with breast cancer and their family and friends can talk with others for friendship and support.
  • Our Real Pink podcast series features candid conversations with breast cancer patients, survivors, researchers, physicians and more.
  • Our fact sheets, booklets and other education materials offer additional information.

Other types of cancer that occur in the breast

Most cancers that occur in the breast are breast cancers (breast carcinomas). This means they started in the milk ducts or the lobules of the breast.

In rare cases, other types of cancer, such as lymphomas (cancer of the lymph system) and sarcomas (cancer of the soft tissues), can occur in the breast. Also, cancers from other sites can metastasize (spread) to the breast.

Some of these cancers are not carcinomas. Others are carcinomas, but they don’t start in the breast. So, they are treated differently and have different risk factors than breast cancer.

For more information on other cancers that can occur in the breast, such as lymphomas, sarcomas and malignant phyllodes tumors, visit the National Cancer Institute’s website.

Updated 03/06/25

This content is regularly reviewed by an expert panel including researchers, practicing clinicians and patient advocates.